bullish

Targovax AS

Targovax - ONCOS-102 set for late-stage development

716 Views27 Jan 2020 17:57
Issuer-paid
SUMMARY

Together with the positive Phase I/II mesothelioma trial, Targovax has introduced a preliminary design for its next trial. The new study will explore ONCOS-102 in triple combination with a checkpoint inhibitor (CPI) and standard chemotherapy. Although plans for the next study are still at a preliminary stage, there is potential for it to become a pivotal programme due to a high unmet need in mesothelioma. The private placement completed on the back of the trial results provides confidence that preparations for advanced ONCOS-102 development in mesothelioma will continue at a strong pace. Consequently, we increase the probability of success and our updated valuation is NOK1.5bn or NOK19.9/share.

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
Logo
Edison Investment Research
Leading International Investment Research
Equities
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x